Quick Answer
Gain Therapeutics, Inc. reported Total Revenue of $55.2 thousand for the year ending 2023.
- Gain Therapeutics, Inc. showed an increase of +0.0% in Total Revenue from 2023 to 2023.
- This data is from Gain Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2020 to 2023 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $6.7 thousand | Q2 2020: $6.4 thousand | Q3 2020: $6.7 thousand | Q1 2021: $5.3 thousand | Q2 2021: $81.6 thousand | Q2 2021: $89.2 thousand | Q3 2021: $16.0 thousand | Q3 2021: $27.3 thousand | Q1 2022: $37.5 thousand | Q1 2022: $45.0 thousand | Q2 2022: $95.1 thousand | Q2 2022: $95.1 thousand | Q1 2023: $55.2 thousand | Q1 2023: $55.2 thousand.
- Over the full 7 years of available data (2020 to 2023), Gain Therapeutics, Inc.'s Total Revenue has grown by 91.1%.
- Historical annual values: Fiscal year 2023: $55.2 thousand | Fiscal year 2023: $55.2 thousand | Fiscal year 2022: $140.1 thousand | Fiscal year 2022: $132.6 thousand | Fiscal year 2021: $133.9 thousand | Fiscal year 2021: $165.0 thousand | Fiscal year 2020: $28.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: